$3.84
(1.10%)
Add to watchlist
Create an alert
Stocks and Shares ISAAlnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
Company Information
About this company
Key people
Yvonne L. Greenstreet
Chief Executive Officer, Director
Jeffrey V. Poulton
Chief Financial Officer, Executive Vice President
Kevin Fitzgerald
Executive Vice President, Chief Scientific Officer, Head - Early Research and Early Development
Robert W. Hesslein
Executive Vice President, Chief Legal Officer, Secretary
Pushkal P. Garg
Executive Vice President, Chief Research and Development Officer
Tolga Tanguler
Chief Commercial Officer
Amy W. Schulman
Independent Chairman of the Board
Stuart A. Arbuckle
Independent Director
Dennis A. Ausiello
Independent Director
Olivier Brandicourt
Independent Director
Margaret A. Hamburg
Independent Director
Click to see more
Key facts
- Shares in issue132.11m
- EPICALNY
- ISINUS02043Q1076
- LocationUnited States
- SectorHealthcare
- IndustryBiotechnology & Drugs
- Market cap$46.87bn
- Employees2,230
- ExchangeNASDAQ
- IndexNASDAQ 100 Index, TR Equity United States Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.